COOPER DEVELOPMENT <BUGS> RESTATES RESULTS Cooper Development Co said it revised results for the year ended October 31 to a loss of 61.7 mln dlrs, or 2.33 dlrs per share, down from the previously-reported loss of 12.1 mln dlrs, or 46 cts per share. The restatement was made because of change in the method of accounting for a combination of several company-controlled concerns that resulted in a 53.5 mln dlr charge, Cooper Development said. Last August Cooper Development combined its Cooper Biomedical Inc unit and its Cooper Laboratories subsidiary with Technicon Instruments Corp, a company acquired from Revlon Inc <REV>, a Cooper spokesman said. The spokesman said the transaction was accounted for as an acquisition, but the Securities and Exchange Commission took issue with the accounting method and said it should be accounted for as a reorganization of entities under common control. This treatment requires that the costs associated with the transaction be expanded rather than capitalized as an intangible asset, the company said. It also said that, since the charged required an expensing of previously accrued liabilities, the company will experience no resulting material change it its cash flow.